This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (403) Pharmacology and Pharmaceutics (111) Digital Pain Assessment and Management (232)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/55129, first published .
Dexmedetomidine Versus Midazolam for End-of-Life Sedation and Agitation: Protocol for a Randomized Controlled Trial (The DREAMS Trial)

Dexmedetomidine Versus Midazolam for End-of-Life Sedation and Agitation: Protocol for a Randomized Controlled Trial (The DREAMS Trial)

Dexmedetomidine Versus Midazolam for End-of-Life Sedation and Agitation: Protocol for a Randomized Controlled Trial (The DREAMS Trial)

Authors of this article:

Benjamin Thomas1, 2 Author Orcid Image ;   Greg Barclay1, 2 Author Orcid Image ;   Wing-Shan Angela Lo2 Author Orcid Image ;   Judy Mullan1 Author Orcid Image ;   Kylie Mansfield1 Author Orcid Image
Article Authors Cited by (2) Tweetations Metrics

Journals

  1. Thomas B, Barclay G, Mansfield K, Mullan J, Lo W. Dexmedetomidine Versus Midazolam for End-of-Life Sedation: The DREAMS Non-Blinded Randomized Clinical Trial. Journal of Pain and Symptom Management 2025;70(5):459 View
  2. Tate H, Ferguson L. Subcutaneous Dexmedetomidine for Refractory Symptoms in a Hospice Inpatient Unit. Journal of Pain and Symptom Management 2025 View